Form 4: Halozyme Therapeutics Legal Officer Reports Routine Equity Vesting and Tax-Related Share Disposition

Mark Howard Snyder, SVP and Chief Legal Officer of Halozyme Therapeutics, Inc. (HALO), reported the vesting of restricted stock units and a subsequent disposition of shares for tax withholding purposes.

Summary

• Mark Howard Snyder, the Senior Vice President and Chief Legal Officer of Halozyme Therapeutics, Inc. (HALO), filed a Form 4 detailing recent transactions.
• On June 12, 2025, Mr. Snyder acquired 5,035 shares of common stock at a price of $0, which resulted from the vesting and settlement of previously granted restricted stock units.
• Concurrently, 2,711 shares of common stock were disposed of at a price of $54.54 per share to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions, Mr. Snyder's direct beneficial ownership of common stock stands at 30,813 shares.
• Additionally, Mr. Snyder holds 15,102 derivative restricted stock units.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document reports routine insider transactions (RSU vesting and tax-related share disposition) which are standard compensation events and do not indicate any unusual positive or negative corporate developments.

Positives

• The vesting of 5,035 restricted stock units indicates a successful milestone for the reporting person, Mark Howard Snyder, converting equity awards into common stock, which is a standard component of executive compensation.

Negatives

• A disposition of 2,711 shares occurred to satisfy tax withholding obligations, which reduced the direct beneficial ownership of common stock by the reporting person.

Future Outlook

The document does not contain any forward-looking statements or guidance.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, common across all publicly traded companies, particularly in the biotechnology and pharmaceutical sectors where equity compensation is prevalent. It does not provide broader industry trends or competitive insights.

Stakeholder Impact

• Shareholders: The transaction represents a routine change in an executive's direct shareholding, with a minor reduction due to tax withholding, which is a common practice and generally has no significant impact on the broader shareholder base.
• Employees: The vesting of RSUs is part of the company's compensation structure, which can be a positive signal for employee retention and motivation, particularly for those with similar equity awards.

Key Dates

Keywords

Halozyme Therapeutics, HALO, SEC Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Share Disposition, Tax Withholding, Executive Compensation